Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2155-2161

  Wang, Zhan ^a   Zhou, Qingyu ^b   Kruh, Gary D ^c   Gallo, James M ^b  

^a TEMPLE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3;

ABCC2 GENE; ABCC3 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG URINE LEVEL; EXPERIMENTAL MODEL; GENE; GENE INACTIVATION; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY TRACT; FECES; LIVER; MALE; METHOTREXATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

MURINAE; MUS;

EID: 80054759110     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041228     Document Type: Article

References (37)

1. Amidon GL, Lennernäs H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227-246.
3. Balis FM, Holcenberg JS, and Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8:202-232. (Pubitemid 13134066)
4. Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26:1481-1487.
5. Borst P, de Wolf C, and van de Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453:661-673. (Pubitemid 46192537)
6. Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592. (Pubitemid 34800230)
7. Braun J and Rau R (2009) An update on methotrexate. Curr Opin Rheumatol 21:216-223.
8. Chan LM, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51. (Pubitemid 38050202)
9. Chessells JM, Leiper AD, Tiedemann K, Hardisty RM, and Richards S (1987) Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child 62:172-176. (Pubitemid 17004200)
10. Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, et al. (2006) Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 317:579-589.
11. Deangelis LM and Iwamoto FM (2006) An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 311-316.
12. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 (Suppl 2):6-9.
13. Fuskevåg OM, Kristiansen C, Olsen R, Aarbakke J, and Lindal S (2000) Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct Pathol 24:325-332.
14. Gerk PM and Vore M (2002) Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 302:407-415. (Pubitemid 34787202)
15. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, and Gallo JM (2007) Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 43:1789-1795. (Pubitemid 46453073)
16. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, et al. (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277-285. (Pubitemid 40676548)
17. Hunter GA (1962) The use of methotrexate in the treatment of psoriasis. Aust J Dermatol 6:248-254.
18. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, and Sugiyama Y (2008) Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J Pharmacol Exp Ther 327:465-473.
19. Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, and Schinkel AH (2010a) P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 16:130-140.
20. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010b) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687-694.
21. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, and Sugiyama Y (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57:3506-3510.
22. Pratt WB, Ruddon RW, Ensminger WD, and Maybaum J (1994) The Anticancer Drugs, 2nd ed, Oxford University Press, New York.
23. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, and McLeod HL (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572-579. (Pubitemid 351500051)
24. Rizzoli V, Mangoni L, Caramatti C, Degliantoni G, and Costi D (1985) High-dose methotrexateleucovorin rescue therapy: selected application in non-Hodgkin's lymphoma. Tumori 71:155-158. (Pubitemid 15081996)
25. Sand TE and Jacobsen S (1981) Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19:453-456. (Pubitemid 11067794)
26. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, and Scheper RJ (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82:193-201. (Pubitemid 34160456)
27. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, and Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 (Suppl):S13-S19.
28. Steele WH, Lawrence JR, Stuart JF, and McNeill CA (1979) The protein binding of methotrexate by the serum of normal subjects. Eur J Clin Pharmacol 15:363-366. (Pubitemid 9235902)
29. van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, and Borst P (2007) Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394. (Pubitemid 47124119)
30. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, et al. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
31. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, and Schinkel AH (2009a) Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15:3084-3093.
32. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, and Schinkel AH (2008) Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 14:8152-8160.
33. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, and Schinkel AH (2009b) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350-3359.
34. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, and Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822. (Pubitemid 15104774)
35. Wu C-Y and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharmacol Res 22:11-23. (Pubitemid 40558141)
36. Xia CQ, Liu N, Yang D, Miwa G, and Gan LS (2005) Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33:637-643. (Pubitemid 40593877)
37. Xia CQ, Milton MN, and Gan LS (2007) Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 8:341-363. (Pubitemid 46780063)